SCHEMBL22553750

SCHEMBL22553750

CN1C(=O)Cc2c(-c3cncc(-c4ccc(N5CCCC5=O)cc4)c3)ccnc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 3/20 0.39
CCNC P24863 2/20 0.39
CDK8 P49336 2/20 0.39
NPC1 O15118 2/20 0.38
PIP4K2A P48426 1/20 0.37
PIM1 P11309 1/20 0.37
CD38 P28907 1/20 0.37
SYK P43405 2/20 0.36
CHEK1 O14757 1/20 0.36
BMPR1B O00238 1/20 0.36
BMPR1A P36894 1/20 0.36
ACVRL1 P37023 1/20 0.36
ACVR1 Q04771 1/20 0.36
ALOX5AP P20292 1/20 0.36
CYP11B1 P15538 2/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22571019 0.83 CYP11B2 (0.39) CYP11B2CCNCCDK8NPC1PIP4K2A
SCHEMBL22553771 0.81 PIP4K2A (0.40) CYP11B2CCNCCDK8NPC1PIP4K2A
SCHEMBL30730847 0.81 PIP4K2A (0.40) CYP11B2CCNCCDK8NPC1PIP4K2A
SCHEMBL22553788 0.79 CD38 (0.39) CYP11B2CCNCCDK8NPC1PIM1
SCHEMBL30730827 0.79 CYP11B2 (0.40) CYP11B2CCNCCDK8NPC1PIP4K2A
SCHEMBL30730852 0.79 CD38 (0.39) CYP11B2CCNCCDK8NPC1PIM1
SCHEMBL22553742 0.79 CYP11B2 (0.40) CYP11B2CCNCCDK8NPC1PIP4K2A
SCHEMBL30730807 0.78 PIP4K2A (0.55) CYP11B2CCNCCDK8NPC1PIP4K2A
SCHEMBL22553945 0.78 PIP4K2A (0.55) CYP11B2CCNCCDK8NPC1PIP4K2A
SCHEMBL22554234 0.77 CCNC (0.41) CYP11B2CCNCCDK8NPC1PIP4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 US claimed
CN-112088157-B Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors 拉文纳制药公司 2023-12-26 CN claimed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US claimed
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 US disclosed
CN-112088157-B Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors 拉文纳制药公司 2023-12-26 CN disclosed
EP-3728230-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 EP disclosed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US disclosed
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2020-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331913-A1 ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS PIP5K1A, PIP5K1B, PIP5K1C CYP11B2 3643/4885CCNC 2067/4885CDK8 1413/4885
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1A, PIP5K1B, PIP5K1C CYP11B2 3643/4885CCNC 2067/4885CDK8 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.